National Bank of Canada
IBRX icon

National Bank of Canada’s ImmunityBio IBRX Stock Holding History

National Bank of Canada’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.63M Buy
3,000
+1,050
+54% +$7.95K ﹤0.01% 1071
2026
Q1 		$1.5M Buy
+1,950
New +$13.3K ﹤0.01% 1156
2025
Q3 		– Sell
-2,800
Closed -$739K – 3024
2025
Q2 		$739K Sell
2,800
-2,120
-43% -$5.7K ﹤0.01% 1345
2025
Q1 		$1.48M Buy
4,920
+1,477
+43% +$4.48K ﹤0.01% 1117
2024
Q4 		$881K Sell
3,443
-6,557
-66% -$27.3K ﹤0.01% 1325
2024
Q3 		$3.72M Buy
10,000
+5,430
+119% +$25.1K ﹤0.01% 895
2024
Q2 		$2.87M Buy
4,570
+3,209
+236% +$21.2K ﹤0.01% 867
2024
Q1 		$1.11M Buy
+1,361
New +$6.16K ﹤0.01% 1119
2023
Q4 		– Sell
-1,193
Closed -$183K – 2799
2023
Q3 		$183K Sell
1,193
-50
-4% -$100 ﹤0.01% 1510
2023
Q2 		$341K Buy
+1,243
New +$3.52K ﹤0.01% 1355

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.36B AUM 18.79% 1-Year Est. Return

National Bank of Canada's IBRX Position: Q2 2026 in Review

National Bank of Canada reduced its ImmunityBio (IBRX) stake by 97% in Q2 2026, selling an estimated $4.46M and leaving 19,818 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #1717.

National Bank of Canada first reported a position in IBRX in Q4 2021 and has held it in 17 quarters since. The position peaked at $4.67M in Q1 2026. 243 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • National Bank of Canada held 19,818 shares of ImmunityBio worth $173K as of Q2 2026.
  • National Bank of Canada sold 588,956 ImmunityBio shares in Q2 2026, an estimated $4.46M.
  • ImmunityBio made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #1717 holding.
  • National Bank of Canada first reported a position in ImmunityBio in Q4 2021 and has held it in 17 quarters since.
  • National Bank of Canada's ImmunityBio position peaked at $4.67M in Q1 2026.
  • 243 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.